Skip to content

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Sponsor is doing this research to find out if an experimental medication, benralizumab, will work and be safe for the treatment of EGPA. To see if benralizumab has an impact in treating EGPA, this study will compare it with an active comparator, mepolizumab, that has regulatory approval in several markets for use in patients with EGPA.

null

Participation Requirements

  • Sex:

    Male, Female, Intersex

  • Eligible Ages:

    18 to 80

Participation Criteria

Inclusion Criteria:
You might be eligible to participate in this trial if:

1) you are 18 years of age and older
2) you have EGPA.
Exclusion Criteria:
You might not be eligible to participate in this trial if:

1) you do not have EGPA
2) you are pregnant
3) you are under the age of 18.

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB19-1821